Genomic Classifiers and Prognosis of Localized Prostate Cancer: A Systematic Review
Preprint
- 6 September 2023
- preprint
- Published by Springer Nature in Research Square
Abstract
Background Refinement of the risk classification for localized prostate cancer is warranted to aid in clinical decision making. A systematic analysis was undertaken to evaluate the prognostic ability of three genomic classifiers, Decipher, GPS, and Prolaris, for biochemical recurrence, development of metastases and prostate cancer specific mortality in patients with localized prostate cancer. Methods Data Sources: MEDLINE, Embase, and Web of Science were queried for reports published January 2010 to April 2022. Study Selection: Prospective or retrospective studies reporting prognosis for patients with localized prostate cancer. Data Extraction: Relevant data were extracted into a customized database by 1 researcher with a second over reading. Risk of bias was assessed using a validated tool for prognostic studies, Quality in Prognosis Studies (QUIPS). Disagreements were resolved by consensus or by input from a third reviewer. We assessed certainty of evidence by GRADE incorporating adaptation for prognostic studies. Results Data Synthesis: A total of 39 studies (37 retrospective) involving over 10 000 patients were identified. Twenty-two assessed Decipher, 5 GPS, and 14 Prolaris. Thirty-four studies included patients who underwent prostatectomy. Based on very low to low certainty of evidence, each of three genomic classifiers modestly improved upon the prognostic ability for biochemical recurrence, development of metastases, and prostate cancer specific mortality compared to standard clinical risk classification schemes Limitations: Downgrading of confidence in the evidence stemmed largely from bias due to the retrospective nature of the studies, heterogeneity in treatment received, and era in which patients were treated (i.e., prior to 2000s). Conclusions: Genomic classifiers provide a small but consistent improvement upon the prognostic ability of clinical classification schemes which may be helpful when treatment decisions are uncertain. However, definitive evidence from current management-era data is needed.Keywords
All Related Versions
This publication has 60 references indexed in Scilit:
- Combined Value of Validated Clinical and Genomic Risk Stratification Tools for Predicting Prostate Cancer Mortality in a High-risk Prostatectomy CohortEuropean Urology, 2015
- Prognostic Utility of the Cell Cycle Progression Score Generated from Biopsy in Men Treated with ProstatectomyJournal of Urology, 2014
- Prognostic Utility of Cell Cycle Progression Score in Men With Prostate Cancer After Primary External Beam Radiation TherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2013
- Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical ProstatectomyPLOS ONE, 2013
- Validation of a Cell-Cycle Progression Gene Panel to Improve Risk Stratification in a Contemporary Prostatectomy CohortJournal of Clinical Oncology, 2013
- Assessing Bias in Studies of Prognostic FactorsAnnals of Internal Medicine, 2013
- Analytical validation of the Oncotype DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsiesBMC Genomics, 2013
- Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohortBritish Journal of Cancer, 2012
- Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective studyThe Lancet Oncology, 2011
- Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate CancerJAMA, 1998